医学
急性心包炎
心包炎
心包积液
心包
心脏压塞
卫生棉条
胸痛
重症监护医学
限制
疾病
外科
心脏病学
内科学
机械工程
工程类
作者
Juan Guido Chiabrando,Aldo Bonaventura,Alessandra Vecchié,George F. Wohlford,Adolfo G Mauro,Jennifer H. Jordan,John D. Grizzard,Fabrizio Montecucco,Daniel Berrocal,Antonio Brucato,Massimo Imazio,Antonio Abbate
标识
DOI:10.1016/j.jacc.2019.11.021
摘要
Pericarditis refers to the inflammation of the pericardial layers, resulting from a variety of stimuli triggering a stereotyped immune response, and characterized by chest pain associated often with peculiar electrocardiographic changes and, at times, accompanied by pericardial effusion. Acute pericarditis is generally self-limited and not life-threatening; yet, it may cause significant short-term disability, be complicated by either a large pericardial effusion or tamponade, and carry a significant risk of recurrence. The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs. Anti-inflammatory treatments vary, however, in both effectiveness and side-effect profile. The objective of this review is to summarize the up-to-date management of acute and recurrent pericarditis. • Pericarditis is the most common disease of the pericardium. Generally self-limiting, pericarditis can be fraught by a significant risk of acute complications and of recurrences. • Prompt diagnosis and appropriate treatment of acute pericarditis may reduce the risk of acute complications and recurrences. • New therapies, such as IL-1 blockers, show promising results in patients with recurrent/refractory pericarditis. • Future studies are needed to deepen the knowledge about pericarditis pathophysiology and provide targeted therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI